05.03.2022 ORYZON starts preclinical collaboration on Kabuki syndrome with Kennedy Krieger Institute and Johns Hopkins University MADRID, SPAIN and CAMBRIDGE, MA, UNITED STATES, May 3rd, 2022 – Oryzon Genomics, S.A. (ISIN Code:...
09.21.2021 Oryzon announces $1 million grant from Kabuki syndrome philanthropists to support a precision medicine Phase I/II trial with Vafidemstat HOPE will be the first clinical trial in precision medicine with vafidemstat in neurodevelopmental diseases...